Compras públicas de medicamentos para hepatite C no Brasil no período de 2005 a 2015

Chaves, Gabriela Costa; Osório-de-Castro, Claudia Garcia Serpa; Oliveira, Maria Auxiliadora

doi:10.1590/1413-81232017228.05602017

Cited by 16 publications

(10 citation statements)

References 3 publications

(2 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Recently, an example of fast change, not exactly compatible with the traditional EM concept [8,36], and with consequences for health outcome, was the rapid incorporation of telaprevir and boceprevir, new DAAs for hepatitis C. At the time, this was perceived as a correct choice, due to existing evidence [37]. However, after very serious adverse effects were identified, these medicines were also rapidly disenfranchisedbut with serious health consequences remaining, as well as considerable costs for the country and a difficult, if not impossible, delisting, due to social pressures [38]. Delisting or moving to second-generation DAAs is now taking place across countries, including Brazil.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Policy Change and the National Essential Medicines List Development Process in Brazil between 2000 and 2014: Has the Essential Medicine Concept been Abandoned?

Osório-de-Castro

Azeredo

Pepe

et al. 2017

Basic Clin Pharma Tox

View full text Add to dashboard Cite

Brazil has had a National Essential Medicines List (EML) since 1964. From 2000 to 2010, five consecutive evidence-based editions were produced, building on the essential medicine concept. In 2012, the government changed course to establish a new paradigm, introducing adoption of new medicines as the main aim within the recommendation process. The objective of the article was to report efforts to develop Brazil's national EML, policy changes from 2000 to 2014, discussing results, challenges and perspectives. Brazilian EML history and development process were collected from legislation, minutes, reports and legal ordinances, from 2000 to 2014. The Brazilian EML and the WHO Model Lists were compared using the Anatomical Therapeutic Chemical system. Overlap between lists was verified, and linear trends were produced. Type of membership, inclusion criteria, procedures, flow and listed medicines varied greatly between the selection committees acting before and after 2012. Paradigm-changing legislation aiming at linking list compliance to public financing in 2012 produced (i) greater importance given to political and administrative stakeholders, (ii) increasing trends in number of medicines over the years, (iii) decrease in use of WHO Model List as a reference and (iv) substitution of an essential medicines list review and update process by an adoption decision output. Other issues remained unchanged. Insufficient efforts for list implementation, such as lack of physician education, presented consequences to the health system. Substantial efforts were made to produce and update the list from 2000 to 2014. However, continuous and intense health litigation disproves process outcome effectiveness.

show abstract

Section: Discussionmentioning

confidence: 99%

“…Delisting or moving to second-generation DAAs is now taking place across countries, including Brazil. The country, faced with growing litigation, has also advanced in forging a disinvestment protocol, fuelled by Conitec [15,37,38].…”

Section: Discussionmentioning

confidence: 99%

Policy Change and the National Essential Medicines List Development Process in Brazil between 2000 and 2014: Has the Essential Medicine Concept been Abandoned?

Osório-de-Castro

Azeredo

Pepe

et al. 2017

Basic Clin Pharma Tox

View full text Add to dashboard Cite

show abstract

“…Na fase contratual, a entrega do encargo e a remuneração de medicamentos também têm maior frequência entre os objetos de PCP investigados nos artigos selecionados, visto que o Brasil é o sétimo mercado farmacêutico do mundo (HOMMA et al, 2013). Estes artigos apresentavam como objetivo a avaliação de estratégias para redução de gastos (MEINERS et al, 2011;CAMPOS;FRANCO, 2017) e maior barganha em situações de monopólio (CHAVES et al, 2017), incremento de transparência no PCP, alinhamento de diferentes políticas de assistência farmacêutica (BEVILACQUA et al, 2011), entre outros.…”

Section: Caracterização Do Processo De Contratação Pública Em Saúdeunclassified

“…Ainda sobre valores praticados, relatórios técnicos que têm por finalidade estimar custos para planejamento de contratação pública em saúde, sofrem de atualizações necessárias para as referidas estimativas, como variações de câmbio e outros impactos nos preços ao tempo da efetivação do gasto (MORAES et al, 2016;CHAVES et al, 2017).…”

Section: Caracterização Do Acesso à Informaçãounclassified

Limitações do acesso à informação sobre contratação pública em saúde no Brasil à luz da Lei de Acesso à Informação

Mota

Júnior

2021

RDBCI rev. dig. Bibliotecon. e Ci. Info.

View full text Add to dashboard Cite

Introdução: Investigar as limitações do acesso às informações sobre contratação pública em saúde no Brasil, no período de 1990 a 2018, de acordo com critérios definidos na Lei de Acesso à Informação. Método: Revisão integrativa da produção científica publicada em periódicos indexados no período supramencionado, com análise dos registros de limitações relatados na busca do acesso às informações sobre contratação pública em saúde, considerando os critérios previstos na referida Lei para garantir o acesso de: primariedade, integridade, atualização, disponibilização e autenticidade. Resultados: Foram incluídos 35 artigos na revisão, com predomínio de estudos sobre a fase externa do processo de contratação pública em saúde, complexidade do objeto de contratação de bens e tendo como contratante as esferas federal e municipal. Identificou-se 64 fontes de informação, sendo a maioria fontes secundárias, no formato de bancos e bases de dados, e 43,75% destas fontes apresentaram relato de limitações em relação ao acesso às informações obtidas. Conclusão: O acesso às informações sobre contratação pública em saúde apresenta limitações importantes em relação à Lei de Acesso à Informação, e tem repercussões sobre a produção do conhecimento científico. A Ciência da Informação pode contribuir com estudos futuros para qualificar os processos de busca e recuperação da referida informação.

show abstract

“…No Brasil, desde a década de 1980, as hepatites virais vêm sendo objeto de preocupação das autoridades sanitárias (Chaves et al, 2017). De acordo com a Organização Mundial da Saúde (OMS), o Brasil é considerado um País de endemicidade intermediária para hepatite C, com prevalência situada entre 2,5 e 10% (Garcia et al, 2012).…”

Section: -Introduçãounclassified

Aspectos clínicos e epidemiológicos dos casos de hepatite C no Estado do Maranhão, Brasil

Oliveira

Holanda

Almeida

et al. 2020

RSD

View full text Add to dashboard Cite

Viral hepatitis is an infectious disease with a high universal morbidity and is an important public health problem. The aim of this study was to analyze the clinical and epidemiological profile of hepatitis C cases in the state of Maranhão. This is an epidemiological, retrospective and descriptive study of a population nature, using secondary data, in which a case study for types C viral hepatitis reported in the period from 2009 to 2018, obtained from the Health Information System of Notification (SINAN). Aspects related to gender, age group, race, education, mechanical source of infection, final classification, clinical forms and laboratory diagnosis and finally the number of cases in the State were evaluated. The data were tabulated using the TABNET and Microsoft Office Excel 2019 programs. During the research period, 1584 cases of hepatitis C were found, where the largest number of cases was in 2011, totaling 223 notifications (14%) and the lowest corresponded to 2017 (5.55%). The individuals most affected by the disease were male (55.7%), aged between 40 and 50 years (53.9%). The predominant ethnic group was mixed race (51.6%) and 25.3% of the patients had completed high school and the main source of infection was sexual (11.6%) and transfusion (10.8%). The chronic form of notified hepatitis C cases corresponded to 89%. While the form of laboratory diagnosis was anti-HCV. These data allow guiding public health decisions, contributing to the planning, management and evaluation of interventions for the control and prevention of hepatitis C in Maranhão.

show abstract

Compras públicas de medicamentos para hepatite C no Brasil no período de 2005 a 2015

Abstract: This paper analyzes the Minister of Health's (MoH)

Cited by 16 publications

References 3 publications

Policy Change and the National Essential Medicines List Development Process in Brazil between 2000 and 2014: Has the Essential Medicine Concept been Abandoned?

Policy Change and the National Essential Medicines List Development Process in Brazil between 2000 and 2014: Has the Essential Medicine Concept been Abandoned?

Limitações do acesso à informação sobre contratação pública em saúde no Brasil à luz da Lei de Acesso à Informação

Aspectos clínicos e epidemiológicos dos casos de hepatite C no Estado do Maranhão, Brasil

Contact Info

Product

Resources

About